Search form
Search
About us
Oxurion at a glance
A word from the CEO and Chairman
Our milestones
Our mission
Part of a global retina community
Our team
Partnerships
Venture projects
Global locations
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Other target diseases
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
THR-687 (pan RGD integrin antagonist)
Science team
Partnerships
Products
Jetrea
Investors
Shareholder Information
Share Price
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
News & Events
Latest news
Conferences & Events
Media contact
Reports & presentations
Contact
Perspectives
Menu
About us
Oxurion at a glance
A word from the CEO and Chairman
Our milestones
Our mission
Part of a global retina community
Our team
Partnerships
Venture projects
Global locations
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Other target diseases
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
THR-687 (pan RGD integrin antagonist)
Science team
Partnerships
Products
Jetrea
Investors
Shareholder Information
Share Price
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
News & Events
Latest news
Conferences & Events
Media contact
Reports & presentations
Contact
Perspectives
Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye
THR-149 - Press Releases archive
1 Sep 2020
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
19 Dec 2019
Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME
9 Sep 2019
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
2 Sep 2019
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
1 Jul 2019
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
24 Apr 2019
Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule
28 Feb 2019
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
25 May 2018
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
23 May 2018
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
6 Apr 2018
ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149
20 Apr 2017
ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema